https://clinicaltrials.gov/ct2/about-studies/glossary
Study completion date
The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "estimated" study completion date is the date that the researchers think will be the study completion date.
I agree that we have exciting times ahead.
Message in reply to:
Clinicaltrials.com is always somewhat behind - the 7/31 date was a target date for Completion of enrollment in the Spanish trial - not sponsored by ECOR but by the investigator. I expect results with weeks of enrollment completion. August/September should prove exciting.
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Recent ECOR News
- electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/03/2024 08:05:00 PM
- electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024 • GlobeNewswire Inc. • 05/01/2024 12:04:51 PM
- Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- electroCore Announces the Launch of Truvaga Plus® for General Wellness • GlobeNewswire Inc. • 04/08/2024 12:30:00 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 04/02/2024 12:00:00 PM
- electroCore Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/13/2024 08:05:00 PM
- electroCore to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024 • GlobeNewswire Inc. • 03/05/2024 09:05:00 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 12:00:51 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:16:30 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 12/26/2023 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 09:15:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 12/18/2023 09:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 10:15:26 PM
- electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/07/2023 12:53:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 11:11:39 AM
- Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023 • GlobeNewswire Inc. • 11/15/2023 01:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:16:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:11:31 PM
- electroCore Announces Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/08/2023 09:01:00 PM
- electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum • GlobeNewswire Inc. • 11/07/2023 01:00:00 PM
- Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM